Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    A randomized, double-blind, placebo-controlled phase III study of regorafenib
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo;   Drug: Best supportive care
2 Completed
Has Results
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo
3 Active, not recruiting Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Condition: Colorectal Neoplasms
Interventions: Drug: Regorafenib (BAY73-4506);   Drug: Placebo
4 Recruiting COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy
Condition: Colorectal Neoplasms
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo
5 Recruiting Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Regorafenib (BAY73-4506);   Drug: Placebo

Indicates status has not been verified in more than two years